cognoa-logo

Cognoa Launches Pivotal Study of the First Digital Diagnostic for Autism.

Palo Alto, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) — Cognoa, a company at the forefront of pediatric behavioral health, announced today initiation of its Pivotal Study to demonstrate the effectiveness of its diagnostic aid for autism spectrum disorder (ASD). The company anticipates submitting the results of this multi-site, prospective, blinded, active comparator study to the U.S. Food and Drug Administration (FDA)…

cognoa-logo

Cognoa and EVERSANA™ announce partnership to advance the commercialization standard for prescription digital medicines.

PALO ALTO, Calif. and CHICAGO, Sept. 10, 2019 /PRNewswire/ — Cognoa, a company at the forefront of pediatric behavioral health, and EVERSANA™, the leading independent provider of global commercial services to the life science industry, today announced a partnership to advance the industry standard by which digital medicines will be ordered, dispensed, and covered by insurance. By leveraging the existing healthcare infrastructure utilized by pharmaceutical companies…

cognoa-logo

Cognoa Licenses Innovative Digital Therapeutic Technology.

PALO ALTO, Calif., April 10, 2019 (GLOBE NEWSWIRE) — Cognoa, a company at the forefront of digital behavioral health for children, today announces it has exclusively licensed technology from the Stanford University School of Medicine to accelerate development and worldwide commercialization of a novel digital therapeutic for children with autism spectrum disorder (ASD). Underscoring the need for earlier access to personalized…

MedTechDive logo

Cognoa’s autism devices win breakthrough status.

FDA has granted breakthrough designations to Cognoa’s digital autism diagnostic and therapeutic devices, the company announced Wednesday. The devices are designed to enable physicians to diagnose autism spectrum disorder (ASD) earlier and improve the social skills and responsiveness of children with the condition. Read full article here.

cognoa-logo

Cognoa Receives FDA Breakthrough Designations for Autism Diagnostic and Digital Therapeutic Devices.

PALO ALTO, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) — Cognoa, a company at the forefront of digital behavioral health for children, today announces it has received Breakthrough Device designations from the U.S. Food and Drug Administration (FDA) for its lead products, the first digital diagnostic and digital therapeutic devices for autism. These products are the foundation of  Cognoa’s precision health platform…

Location

Social